Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) tinted gains of +2.72% (+1.13 points) to US$42.71. The volume of 0.52 Million shares climbed down over an trading activity of 589.11 Million shares. EPS ratio determined by looking at last 12 month figures is -6.02. Over the same time span, the stock marked US$74.75 as its best level and the lowest price reached was US$32.18. The corporation has a market cap of US$1.87 Billion.
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI)’s earnings per share has been growing at a 24.2 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -114.7 percent while most common profitability ratio return on investment (ROI) was 0 percent. The company’s institutional ownership is monitored at 0 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 97.3 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 4 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 1 think it is Hold. Recently, analysts have updated the overall rating to 1.73. 6 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Jaguar Health, Inc. (NASDAQ:JAGX) is worth US$5.98 Million and has recently risen 2.71% to US$0.28. The latest exchange of 0.42 Million shares is below its average trading activity of 775.4 Million shares. The day began at US$0 but the price moved to US$0 at one point during the trading and finally capitulating to a session high of US$0. The stock tapped a 52-week high of US$6.6 while the mean 12-month price target for the shares is US$1.25.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 0.33, and a price to sales ratio of 1.36. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 0%. With an institutional ownership near 18.7%, it carries an earnings per share ratio of -5.21.